Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.
Abstract
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide. These agents have been shown to reduce A1C (by ∼0.8–1.6%), body weight (by ∼1–3 kg), blood pressure, and lipids. GLP-1 receptor agonists are associated with a low risk of hypoglycemia, and the most common adverse effects are gastrointestinal. Proper patient selection and education can assist in achieving positive treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GI AE profile of semaglutide 2.4 mg in the STEP trials is consistent with previous observations with lower semaglutide doses and the established AE profile of GLP‐1RAs. 14 , 28 , 29”
From Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As higher incidences of GI AEs tend to be experienced with higher doses of GLP‐1RAs, gradual dose escalation and dose adjustment may help mitigate the impact of GI AEs in clinical practice. 29 , 30”
In the citing paper
“GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements to β-cell function and peripheral insulin sensitivity ( Zander et al., 2002 ; Hinnen, 2017 ).”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Hinnen, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similar positive cardiovascular results were reported recently for semaglutide, an investigational GLP-1 receptor agonist administered QW (33).”
ResultMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Two incretin hormones have been identified: glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) (4).”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“O R G The incretin system has become an important target in the treatment of type 2 diabetes in recent years (1).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is reduced in people with type 2 diabetes (6).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Intravenous administration of exogenous GLP1 to patients with type 2 diabetes was shown to reduce plasma glucose concentrations to the normal fasting range, even in patients who had an inadequate response to oral antihyperglycemic drugs (10).”
BackgroundGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878 · cited 3×
“Place in Therapy According to the AACE/ACE and ADA diabetes treatment algorithms for glycemic control (36,37), GLP-1 receptor agonists are recommended as add-on therapy for patients who do not achieve their A1C target after 3 months of metformin therapy.”
InfluentialPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“It has been shown that secretion of insulin is greater in response to oral glucose ingestion than to an isoglycemic intravenous glucose infusion, a phenomenon referred to as “the incretin effect” (2,3).”
BackgroundStandards of Medical Care in Diabetes
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s15 · Cited by 683
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“• No cases of medullary thyroid carcinoma have been reported in clinical trials of GLP-1 receptor agonists; however, based on thyroid C-cell hyperplasia, adenomas, and medullary thyroid carcinomas observed in studies of these agents in mice (40), all of the GLP-1 receptor agonists except exenatide BID and lixisenatide…”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629 · cited 1×
“The 2015 American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) clinical practice guidelines also note the importance of weight management in patients with type 2 diabetes and recommend the use of antihyperglycemic agents that are associated with weight loss or at least ha…”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · cited 1×
“Administration of GLP-1 receptor agonists stimulates GLP-1 receptors, thereby increasing insulin secretion in response to oral and intravenous glucose to similar extents; this means the magnitude of the incretin effect should remain unchanged (8).”
BackgroundPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498 · cited 1×
“The FDA and the European Medicines Agency concluded that available data were not consistent with a causal association between incretin-based therapies and pancreatitis, but data on the pancreatic effects continue to be monitored (41).”
BackgroundFox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0012 · Cited by 492
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-er09 · Cited by 379
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 1×
“24] for albiglutide 30 mg) compared to placebo (34).”
BackgroundGibney, M. A., Arce, C. H., Byron, K. J., & Hirsch, L. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.481203 · Cited by 283
Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1393 · Cited by 251
DeYoung, M. B., MacConell, L., Sarin, V., Trautmann, M., & Herbert, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0050 · Cited by 241
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230 · cited 1×
“GLP-1 GLP-1 has a number of potentially beneficial effects in the setting of type 2 diabetes (Figure 1) (9).”
BackgroundAbstract #100: Acth-Secreting Pheochromocytoma
Kalia-Reynolds, M., Giordano, J., Kalia-Reynolds, I., & Houston, C. (2015) · Endocrine Practice · doi:10.1016/s1530-891x(20)42300-6 · Cited by 208
Glucagon-like peptide-1 analogues: An overview
Gupta, V. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111625 · Cited by 186 · cited 1×
“The development of GLP-1 receptor agonists that are resistant to degradation overcame this limitation (12).”
BackgroundMonami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12175 · Cited by 174 · cited 1×
“As noted above, meta-analysis findings suggest no increased risk of major adverse cardiovascular events in patients receiving GLP-1 receptor agonists, and there is some suggestion of potential benefit (29).”
ResultNew injection recommendations for patients with diabetes
Frid, A., Hirsch, L., Gaspar, R., Hicks, D., Kreugel, G., Liersch, J., Letondeur, C., Sauvanet, J. P., Tubiana-Rufi, N., & Strauss, K. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70002-1 · Cited by 172
Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163 · cited 1×
“5 kg), with no significant differences among these three treatments (24).”
BackgroundSecretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158 · cited 1×
“The most recent understanding of this deficit suggests that it relates to deterioration of the GLP-1 effect, with impaired capacity to secrete insulin, increasing insulin resistance, and hyperglycemia, perhaps leading to a decrease in GLP-1 receptor expression and resulting in GLP-1 resistance (7).”
BackgroundMearns, E. S., Sobieraj, D. M., White, C. M., Saulsberry, W. J., Kohn, C. G., Doleh, Y., Zaccaro, E., & Coleman, C. I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125879 · Cited by 154
Buse, J. B., Garber, A., Rosenstock, J., Schmidt, W. E., Brett, J. H., Videbæk, N., Holst, J., & Nauck, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2822 · Cited by 154
Fineman, M., Mace, K., Diamant, M., Darsow, T., Cirincione, B., Porter, T. K. B., Kinninger, L. A., & Trautmann, M. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01561.x · Cited by 151
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143 · cited 1×
“As reviewed by Saraiva and Sposito (28), a number of findings indicate that GLP-1 receptor agonists do not worsen CVD and may have broader potential cardiovascular benefits in patients with type 2 diabetes.”
BackgroundTherapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 110 · cited 1×
“GLP-1 receptor agonists are well suited for early use in type 2 diabetes because they stimulate release of insulin and suppress glucagon secretion only when blood glucose concentrations are elevated; thus, the risk of hypoglycemia is low (38).”
BackgroundHirsch, L. J., Gibney, M. A., Albanese, J., Qu, S., Kassler-Taub, K., Klaff, L. J., & Bailey, T. S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.482499 · Cited by 109
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J., Sourij, H., Doran, Z., Keenan, J., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 108
Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
Acosta, A., Camilleri, M., Burton, D., O'Neill, J., Eckert, D., Carlson, P., & Zinsmeister, A. R. (2015) · Physiological Reports · doi:10.14814/phy2.12610 · Cited by 78 · cited 1×
“In a study of obese patients with accelerated gastric emptying, treatment with exenatide BID for 30 days resulted in slowed gastric emptying and a modest reduction in caloric intake compared to placebo (25).”
BackgroundGiorda, C. B., Sacerdote, C., Nada, E., Marafetti, L., Baldi, I., & Gnavi, R. (2014) · Endocrine · doi:10.1007/s12020-014-0386-8 · Cited by 75
Hauber, B., Nguyen, H. P., Posner, J., Kalsekar, I. D., & Ruggles, J. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1117433 · Cited by 66 · cited 1×
“Needle gauge requirements vary by product but are not believed to be the main factor affecting patient preference (39).”
BackgroundWang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12386 · Cited by 62
Kayaniyil, S., Lozano‐Ortega, G., Bennett, H. A., Johnsson, K. M., Shaunik, A., Grandy, S., & Kartman, B. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0155-1 · Cited by 43
The potential role of glucagon-like peptide 1 in diabetes.
Meier, J. J., & Nauck, M. A. (2004) · PubMed · Cited by 39
Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., & Mace, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12640 · Cited by 32
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Nauck, M. A., Kristensen, P. L., Ravn, L. S., Bergenstal, R. M., Pocock, S., Poulter, N. R., Zinman, B., Steinberg, W. M., Frandsen, K. B., Buse, J. B., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/5vsp-zn15 · Cited by 14
Research works printed but not linked: 2
- Johnson, 2014, Integrated phase 3 immunogenicity results for albiglutide, Diabetes, 63, A427
- Milicevic, 2015, Low incidence of anti-drug antibody in type 2 diabetes patients treated with once-weekly dulaglutide, Diabetes, 64, A292
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297
Metadata
- Authors
- Hinnen, D.
- Affiliations
- University of Colorado Health (US)
- Corresponding author
- Hinnen, Deborah
- ORCID
- Hinnen, Deborah
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2017-08-01
- Volume
- 30
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC5556578
- OpenAlex
- W2592545469
- Cited by
- 394
- References
- 53
- Citations by year
- 2026: 23 · 2025: 71 · 2024: 59 · 2023: 57 · 2022: 53 · 2021: 59 · 2020: 46 · 2019: 22 · 2018: 3 · 2017: 1
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- AstraZeneca
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, incretin system, exenatide, liraglutide, lixisenatide, exenatide extended-release, albiglutide, dulaglutide, glycemic control, weight loss, hypoglycemia risk, gastrointestinal adverse effects, patient selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.